Jaguar Health Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 2/6
Jaguar Health has a total shareholder equity of $19.1M and total debt of $32.9M, which brings its debt-to-equity ratio to 172.7%. Its total assets and total liabilities are $61.5M and $42.4M respectively.
Anahtar bilgiler
172.7%
Borç/özkaynak oranı
US$32.93m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$16.05m |
| Eşitlik | US$19.06m |
| Toplam yükümlülükler | US$42.40m |
| Toplam varlıklar | US$61.46m |
Son finansal sağlık güncellemeleri
Recent updates
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
May 24Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Mar 29Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Jan 22Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
Jun 10Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
Jan 23Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment
Oct 17Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront
Aug 25Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule
Aug 19Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea
Aug 09Jaguar stock rises on license deal with SynWorld for Canalevia in China
Jun 29Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory
Mar 07Jaguar Health shares jumps 13% after pricing $15M direct offering
Jan 13Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients
Jan 11Jaguar Health leaps higher in new year
Jan 05Jaguar Health inks second Mytesi royalties agreement for $6M
Dec 23Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?
Dec 02
Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%
Nov 30Jaguar Health EPS misses by $0.10, misses on revenue
Nov 16Jaguar Health receives positive Nasdaq listing determination
Oct 29Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: JAGX's short term assets ($40.1M) exceed its short term liabilities ($19.1M).
Uzun Vadeli Yükümlülükler: JAGX's short term assets ($40.1M) exceed its long term liabilities ($23.3M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: JAGX's net debt to equity ratio (88.5%) is considered high.
Borcun Azaltılması: JAGX's debt to equity ratio has increased from 153.9% to 172.7% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: JAGX has less than a year of cash runway based on its current free cash flow.
Tahmini Nakit Akışı: JAGX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.6% each year